Clinical research is, in theory, the backbone of modern medicine: the bridge between scientific discovery and life-saving treatments. Brazil, with its centers of excellence, highly trained researchers and a large, diverse population, seemed to hold all the cards. Seemed. In practice, the country turned this advantage into a textbook case of squandered opportunity: billions in investment evaporated while patients were left on the sidelines of innovative therapies, trapped in a bureaucratic maze and a regulatory framework better suited to a museum.
For years, the story barely changed. While the United States and Europe approved clinical trials within weeks, Brazil let deadlines stretch into months — sometimes years. The price of this inertia? More than R$2 billion lost annually in investment, not to mention the reputation of a country that preferred paralysis to science. This is not a technical footnote; it is a real delay for patients and an official seal of administrative incompetence.
Only now, after more than a decade of fruitless debate, has Law 14,715/2023 arrived — a breath of modernity that somehow escaped Brazil’s health system until now. The congressional reversal of a presidential veto limiting the supply of trial drugs to five years feels almost like a legislative miracle — or perhaps just the bare minimum for a country that wants to be taken seriously.
Let’s not be fooled: the law does offer predictability and investor appeal, but it also exposes how far behind Brazil has fallen. A country that could have positioned itself as a hub for health innovation instead became a cautionary tale of bureaucratic melodrama. Now, at least on paper, Conep (the ethics body for human research) and Anvisa (the national health regulator) are expected to move in sync, streamlining approvals and giving patients somewhat faster access to cutting-edge therapies.
But the real test starts now. Without swift regulation from the Health Ministry, this breakthrough risks becoming yet another decorative ornament in Brazil’s legal framework — the kind that fills reports but changes nothing on the ground. The five-year limit for sponsors to supply treatments is indeed a powerful incentive, but it will only work if the public health system and private insurers move as quickly as foreign trial sponsors are expected to.
Meanwhile, the world does not wait. In the United States, billions flow into clinical research every year under clear and predictable rules. In Brazil, we celebrate the basics: the chance to lose a little less. The new framework is a step forward, but also an uncomfortable reminder of how many steps we have fallen behind.
If all goes well, the country could finally reap benefits: more trials, skilled jobs, a stronger health industrial complex and, above all, better outcomes for patients. But if the law remains ink on paper, it will be yet another victory for rhetoric — not for science.
Nelson Mussolini, executive president of Sindusfarma, the union representing Brazil’s pharmaceutical industry
(The opinions expressed in this article are the sole responsibility of the author and do not necessarily reflect the position of Brazil Stock Guide)
Leave a Reply